Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2020

Open Access 01.12.2020 | Research

Association between number of dissected lymph nodes and survival in stage IA non-small cell lung cancer: a propensity score matching analysis

verfasst von: Lei-Lei Wu, Jia-Jian Lai, Xuan Liu, Yang-Yu Huang, Peng Lin, Hao Long, Lan-Jun Zhang, Guo-Wei Ma

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2020

Abstract

Background

For patients with stage IA non-small cell lung cancer (NSCLC) with tumor size ≤ 2 cm, the prognostic significance of the number of removed lymph nodes (NLNs) through different surgical methods remains unclear. To determine the association of NLNs with cancer-specific survival (CSS) and overall survival (OS) in patients with stage IA NSCLC with tumor size ≤ 2 cm who underwent different lung surgeries.

Methods

We retrospectively enrolled 7293 patients from the Surveillance, Epidemiology and End Results database. Median NLNs was used to classify the patients into two groups: group A with NLNs ≤ 5 and group B with NLNs > 5. Propensity score matching (PSM) was performed to decrease selection bias. Kaplan–Meier analysis and Cox regression analysis were performed to identify the association between NLNs and survival outcomes.

Results

Group B had better survival than group A in the unmatched cohort and matched cohort (all P < 0.05). Multivariable analyses revealed that the NLNs significantly affected CSS and OS of eligible cases in the unmatched cohort and matched cohort. Additionally, we found that the NLNs was a protective prognostic predictor of OS for patients who underwent wedge resection, segmental resection, or lobectomy.

Conclusion

The NLNs was a protective prognostic factor in NSCLC patients with tumor size ≤ 2 cm. We demonstrated that patients with > 5 NLNs in the cohort of wedge resection, segmental resection, or lobectomy exhibited a significantly better OS.
Hinweise
Lei-Lei Wu and Jia-Jian Lai contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
NSCLC
Non-small cell lung cancer
NLNs
The number of removed lymph nodes
CSS
Cancer-specific survival
OS
Overall survival
SEER
Surveillance, Epidemiology, and End Results database
PSM
Propensity score matching
AJCC
American Joint Committee on Cancer
LNs
Lymph nodes
CT
Computed tomography
LC
Lung cancer
HR
Hazard ratio
CIs
Confidence intervals
SD
Standard deviation
Lung NOS
Uncertain location on lung
Adeno
Adenocarcinoma
SCC
Squamous cell carcinoma
LCC
Large cell carcinoma
PSC
Pulmonary sarcomatoid carcinoma
Other
Other histological types
Inf
Infinity

Introduction

Lung cancer is one of the most aggressive malignancies worldwide. In 2019, lung cancer accounted for 13% of all estimated new cancer cases and one-quarter of all estimated cancer deaths in adults [1]. Patients with stage IA (according to 8th American Joint Committee on Cancer [AJCC] Staging Manual) non-small-cell lung cancer (NSCLC) may undergo different surgical treatments, such as wedge resection, segmental resection, lobectomy, or pneumonectomy; however, their 5-year overall survival rate remains around 73–90% [2]. Lobectomy along with mediastinal lymph nodes (LNs) resection has been considered the standard surgical treatment for early-stage NSCLC for more than 2 decades [3]. LNs’ dissection is widely used to determine the accurate pathologic staging of NSCLC and to provide guidance regarding the prognosis and additional treatments. Multiple studies have indicated that LN resection conferred benefit in terms of the survival outcomes of patients with stage T1-4N0M0 NSCLC [48]. Furthermore, it seems that the dissection of more number of LNs may result in a clearer TNM classification and improve the survival outcomes of patients [9, 10].
Whereas with the popularization of computed tomography (CT)-based screening and application of some CT features, the predictive ability to distinguish benign and malignant lesions of small pulmonary nodules has significantly improved [1113]. Patients with clinical stage I NSCLC commonly undergo lung cancer screening by CT, which helps detect the pulmonary nodules. Recently, the results of JCOG0804 demonstrated that for patients who were found with a lesion with a diameter ≤ 2 cm and a solid component ≤ 25%, the 5-year disease-free survival rate of those patients with sub-lobectomy was 99.7% [14]. Therefore, surgeons and patients might consider sub-lobar resection, including wedge resection, and segmental resection as a preferred treatment approach to protect more healthy tissues in the lung. However, with increased sub-lobar resection, the decision to include LN dissection remains controversial. In addition, few studies have investigated the relationship between LN resection and the survival outcomes of patients with clinical stage IA (8th AJCC) NSCLC with tumor size ≤ 2 cm who underwent different types of lung surgery (wedge resection, segmental resection, lobectomy, pneumonectomy) [7].
Therefore, we aimed to investigate whether resection of more LNs resulted in better survival outcomes among patients with clinical stage IA NSCLC with tumor size ≤ 2 cm and to determine the effects of the number of removed lymph nodes (NLNs) on conferring survival benefit to patients who underwent wedge resection, segmental resection, lobectomy, or pneumonectomy.

Materials and methods

Patients

This study was a retrospective study and approved by the Clinical Research Ethics Committee of Sun Yat-sen University Cancer Center (IRB number: B2019-116-01), and the need for informed consent of patients was waived. Between 2004 and 2015, 7293 patients with stage IA NSCLC and tumor size ≤ 2 cm from the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively included in this study. The clinical TNM classifications were based on the 8th edition AJCC classification criteria. The inclusion criteria were as follows: (1) pathologically diagnosed as lung cancer (LC), (2) complete follow-up, (3) virtual survival status and clear survival time, (4) first malignancy and one primary, (5) diagnosis between 2004 and 2015, (6) primary non-small cell lung cancer, and (7) patients with clinical stage IA. The exclusion criteria were as follows: (1) Unknown 8th AJCC TNM stage, (2) diagnosed as small cell lung cancer, (3) stage other than IA, (4) tumor size more than 20 mm, (5) dead within 1 month, (6) did not receive lung resection, (7) follow-up of alive cases was within 60 months, (8) unknown information on lymph node resection, (9) had radiotherapy records, and (10) had chemotherapy records.

Data collection

SEER is a population-based cancer registry that is made up of 18 geographically distinct tumor registries and covers 26% of the United States population. The data that supported the findings of this study are available in SEER Stat software (version 8.3.8), reference number: SEER 18 Regs Custom Data, Nov Sub (1975-2016 varying).

Statistical analyses

The baseline characteristics between the two groups were evaluated using the chi-squared test, Fisher’s exact test, and Student’s t test. Both Kaplan–Meier analysis and the log-rank test were used to investigate the role of NLNs in cancer-specific survival (CSS) and overall survival (OS). Univariable and multivariable Cox regression analyses were performed to test the significant variables associated with CSS and OS. All statistical tests were two-sided, and probability values (p value) < 0.05 were considered statistically significant. Hazard ratio (HR) alongside 95% confidence intervals (CIs) was used to present the relative risk of the factors. Standard deviation (SD) was used to evaluate the stability of data in this cohort. The cutoff point of NLNs was determined using the median. Besides, to improve the test level and minimize the selection bias of the study, a 1:1 patient paired propensity score matching (PSM) analysis was performed. Age at diagnosis (age), sex, race/ethnicity, tumor size, TNM stage, grade, histological types, and surgical approaches were considered as covariates in the PSM model. With PSM, 2350 pairs were generated from 7293 eligible patients. All data in this study were analyzed using R (3.6.1) (https://​www.​r-project.​org/​).

Results

Patient characteristics

A total of 7293 eligible patients were enrolled in this study. The flow chart of this study is shown in Fig. 1. The median size of the tumor was 1.5 cm (range 0.1–2.0 cm). Similarly, the mean tumor size was 1.5 cm (SD 0.4 cm). Meanwhile, the median NLNs was 5 (range 0–78) and the mean NLNs was 6.72 (SD 6.88). The patients were divided into two groups according to the median NLNs. A total of 3850 patients had ≤ 5 LNs dissected, whereas 3443 patients had > 5 LNs dissected. Table 1 shows the baseline characteristics of patients stratified by NLNs (≤ 5 and > 5) before and after PSM. Before PSM, a significant difference between the two groups was seen in terms of age (P < 0.001), stage (P = 0.004), tumor location (P < 0.001), tumor size (P < 0.001), and surgical methods (P < 0.001). With PSM, 2350 pairs of patients were eligible for analysis and further stratified by the NLNs (≤ 5 and > 5). Because of PSM, both groups were well balanced as all the variables were not significantly different between groups.
Table 1
Baseline characteristics of patients with stage IA NSCLC ≤ 2 cm in size stratified by NLNs without and with PSM
 
Without PSM
With PSM
Groups
NLNs ≤ 5
NLNs > 5
p value
NLNs ≤ 5
NLNs > 5
p value
Total
3850
3443
 
2350
2350
 
Sex (%)
  
0.437*
  
0.423*
 Male
1588 (41.2%)
1452 (42.2%)
 
968 (41.2%)
940 (40.0%)
 
 Female
2262 (58.8%)
1991 (57.8%)
 
1382 (58.8%)
1410 (60.0%)
 
Age (%)
  
< 0.001*
  
0.906*
 ≤ 65
1468 (38.1%)
1517 (44.1%)
 
990 (42.1%)
985 (41.9%)
 
 > 65
2382 (61.9%)
1926 (55.9%)
 
1360 (57.9%)
1365 (58.1%)
 
TNM stage (%)
  
0.004*
  
1*
 IA1
703 (18.3%)
541 (15.7%)
 
349 (14.9%)
350 (14.9)
 
 IA2
3147 (81.7%)
2902 (84.3%)
 
2001 (85.1%)
2000 (85.1%)
 
Grade (%)
  
< 0.001*
  
0.707*
 I
841 (21.8%)
774 (22.5%)
 
525 (22.3%)
530 (22.6%)
 
 II
1622 (42.1%)
1569 (45.6%)
 
1045 (44.5%)
999 (42.5%)
 
 III
992 (25.8%)
847 (24.6%)
 
578 (24.6%)
609 (25.9%)
 
 IV
55 (1.4%)
37 (1.1%)
 
32 (1.4%)
32 (1.4%)
 
 Unknown
340 (8.8%)
216 (6.3%)
 
170 (7.2%)
180 (7.7%)
 
Tumor location (%)
  
< 0.001**
  
1**
 Upper lobe
2258 (58.6%)
2289 (66.5%)
 
1388 (59.1%)
1395 (59.4%)
 
 Middle lobe`
311 (8.1%)
148 (4.3%)
 
148 (6.3%)
146 (6.2%)
 
 Lower lobe
1216 (31.6%)
965 (28.0%)
 
783 (33.3%)
777 (33.1%)
 
 Main bronchus
5 (0.1%)
4 (0.1%)
 
1 (0.0%)
1 (0.0%)
 
 Overlapping
16 (0.4%)
12 (0.3%)
 
10 (0.4%)
10 (0.4%)
 
 Lung NOS
44 (1.1%)
25 (0.7%)
 
20 (0.9%)
21 (0.9%)
 
Tumor size (mean (SD) (mm))
14.72 (4.03)
15.05 (3.86)
< 0.001***
15.12 (3.88)
15.08 (3.81)
0.690***
Race (%)
  
0.059**
  
0.972**
 American Indian
15 (0.4%)
14 (0.4%)
 
10 (0.4%)
12 (0.5%)
 
 Asian
194 (5.0%)
203 (5.9%)
 
141 (6.0%)
148 (6.3%)
 
 Black
324 (8.4%)
239 (6.9%)
 
197 (8.4%)
196 (8.3%)
 
 White
3308 (85.9%)
2983 (86.6%)
 
3 (0.1%)
4 (0.2%)
 
 Unknown
9 (0.2%)
4 (0.1%)
 
1999 (85.1%)
1990 (84.7%)
 
Surgical methods (%)
  
< 0.001**
  
1**
 Wedge resection
1417 (36.8%)
230 (6.7%)
 
230 (9.8%)
230 (9.8%)
 
 Segmental resection
284 (7.4%)
80 (2.3%)
 
79 (3.4%)
79 (3.4%)
 
 Lobectomy
2126 (55.2%)
3102 (90.1%)
 
2030 (86.4%)
2030 (86.4%)
 
 Pneumonectomy
17 (0.4%)
28 (0.8%)
 
11 (0.5%)
11 (0.5%)
 
 Unknown
6 (0.2%)
3 (0.1%)
 
0 (0.0%)
0 (0.0%)
 
Histological types (%)
  
0.157**
  
0.866**
 Adeno
2503 (65.0%)
2297 (66.7%)
 
1592 (67.7%)
1565 (66.6%)
 
 SCC
861 (22.4%)
745 (21.6%)
 
494 (21.0%)
510 (21.7%)
 
 LCC
117 (3.0%)
74 (2.1%)
 
56 (2.4%)
60 (2.6%)
 
 PSC
3 (0.1%)
2 (0.1%)
 
1 (0.0%)
0 (0.0%)
 
 Other
222 (5.8%)
210 (6.1%)
 
134 (5.7%)
136 (5.8%)
 
 Unknown
144 (3.7%)
115 (3.3%)
 
73 (3.1%)
79 (3.4%)
 
NSCLC non-small cell lung cancer, NLNs the number of removed lymph nodes, PSM propensity score matching, Lung NOS uncertain location on lung, Adeno adenocarcinoma, SCC squamous cell carcinoma, LCC large cell carcinoma, PSC pulmonary sarcomatoid carcinoma, Other other histological types
*Chi-squared test
**Fisher’s exact test
***Student’s t test

Effect of NLNs on survival outcomes

Kaplan–Meier analysis and log-rank tests were performed to investigate the effect of NLNs on CSS and OS in the eligible patients without and with PSM. The analysis revealed a common trend in the unmatched and matched cohorts; patients with > 5 NLNs (group B) showed significantly better CSS and OS than those patients with ≤ 5 NLNs (group A) (all p values < 0.001) (Fig. 2). Precisely, in the unmatched cohort, the 1-, 3-, and 5-year CSS of group A (NLNs ≤ 5) were 94.8%, 84.4%, and 77.3%, respectively, while the corresponding values of group B (NLNs > 5) were 96.6%, 89.5%, and 84.1%. Similarly, the 1-, 3-, and 5-year OS of group A (NLNs ≤ 5) were 90.2%, 73.4%, and 60.5%, respectively, while the corresponding values for group B (NLNs > 5) were 92.3%, 80.0%, and 70.4%. Likewise, after PSM, 1-, 3-, and 5-year CSS of group A (NLNs ≤ 5) were 93.3%, 83.0%, and 76.1%, respectively, while the corresponding values for group B (NLNs > 5) were 96.3%, 88.7%, and 83.3%. As for OS, 1-, 3-, and 5-year OS of group A (NLNs ≤ 5) were 87.4%, 71.5%, and 59.7%, respectively, while the corresponding values for group B (NLNs > 5) were 92.3%, 79.7%, and 69.7%.
To further validate the impact of NLNs on OS and CSS, univariable and multivariable analyses were conducted in the unmatched and matched cohorts. Without PSM, the univariable analysis revealed that NLNs, sex, age at diagnosis, TNM stage, grade, tumor size, surgical methods, and histological types were associated with CSS while NLNs, sex, age at diagnosis, TNM stage, grade, tumor location, tumor size, race/ethnicity, surgical methods, and histological types were associated with OS of the patients (Table 2). In addition, the multivariable analysis also revealed that NLNs, sex, age at diagnosis, grade, tumor size, surgical methods, and histological types independently predicted both CSS and OS (Table 2). After PSM, the univariable analysis confirmed that NLNs, sex, age at diagnosis, TNM stage, grade, tumor size, surgical methods, and histological types were statistically significant predictors for CSS and OS. In addition, the multivariable Cox regression analysis also revealed that NLNs, sex, age at diagnosis, grade, surgical methods, and histological types were independent predictors for CSS and OS (Table 3). In summary, univariable and multivariable analyses uniformly indicated that the NLNs were a significant and independent prognostic factor in the unmatched and matched patients.
Table 2
The association between NLNs and CSS together with OS in univariate and multivariate analyses without PSM
 
CSS
OS
Variable
Number
Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
p value
HR (95%CIs)
p value
p value
HR (95%CIs)
p value
NLNs
 ≤ 5
3850
 
1 (reference)
  
1 (reference)
 
 > 5
3443
< 0.001
0.791 (0.710–0.882)
< 0.001
< 0.001
0.821 (0.763–0.884)
< 0.001
Sex
 Male
3040
 
1 (reference)
  
1 (reference)
 
 Female
4253
< 0.001
0.757 (0.686–0.835)
< 0.001
< 0.001
0.723 (0.676–0.773)
< 0.001
Age
 ≤ 65
2985
 
1 (reference)
  
1 (reference)
 
 > 65
4308
< 0.001
1.548 (1.393–1.720)
< 0.001
< 0.001
1.946 (1.806–2.096)
< 0.001
TNM stage
 IA1
1244
 
1 (Reference)
  
1 (Reference)
 
 IA2
6049
0.003
1.023 (0.843–1.243)
0.815
< 0.001
1.038 (0.911–1.182)
0.578
Grade
 I
1615
 
1 (reference)
  
1 (reference)
 
 II
3191
< 0.001
2.109 (1.794–2.479)
< 0.001
< 0.001
1.631 (1.471–1.807)
< 0.001
 III
1839
< 0.001
2.810 (2.364–3.341)
< 0.001
< 0.001
2.004 (1.792–2.242)
< 0.001
 IV
92
< 0.001
1.476 (0.911–2.392)
0.113
< 0.001
1.303 (0.944–1.797)
0.107
 Unknown
556
< 0.001
1.785 (1.414–2.253)
< 0.001
< 0.001
1.407 (1.207–1.640)
< 0.001
Tumor location (%)
 Upper lobe
4547
    
1 (Reference)
 
 Middle lobe
459
0.597
  
0.017
0.895 (0.773–1.036)
0.138
 Lower lobe
2181
0.794
  
0.712
1.038 (0.964–1.119)
0.320
 Main bronchus
9
0.427
  
0.351
0.800 (0.257–2.485)
0.699
 Overlapping
28
0.821
  
0.431
1.429 (0.859–2.378)
0.169
 Lung NOS
69
0.176
  
0.148
1.114 (0.811–1.530)
0.506
Tumor size (mm)
< 0.001
1.022 (1.004–1.041)
0.015
< 0.001
1.018 (1.005–1.030)
0.005
Race
 American Indian
29
    
1 (Reference)
 
 Asian
397
0.725
  
0.160
0.613 (0.346–1.083)
0.092
 Black
563
0.410
  
0.742
0.962 (0.551–1.679)
0.890
 White
6291
0.548
  
0.747
0.920 (0.533–1.587)
0.764
 Unknown
13
0.981
  
0.049
0.150 (0.020–1.150)
0.068
Surgical methods
 Wedge resection
1647
 
1 (reference)
  
1 (reference)
 
 Segmental resection
364
0.397
0.944 (0.757–1.178)
0.610
0.009
0.841 (0.721–0.981)
0.027
 Lobectomy
5228
< 0.001
0.719 (0.637–0.812)
< 0.001
< 0.001
0.696 (0.641–0.756)
< 0.001
 Pneumonectomy
45
0.033
1.957 (1.183–3.238)
0.009
0.030
1.623 (1.137–2.315)
0.008
 Unknown
6
0.426
0.430 (0.060–3.061)
0.399
0.284
0.567 (0.182–1.763)
0.327
Histological types
 Adeno
4800
 
1 (reference)
  
1 (reference)
 
 SCC
1606
< 0.001
1.046 (0.926–1.182)
0.470
< 0.001
1.376 (1.271–1.490)
< 0.001
 LCC
191
< 0.001
1.666 (1.276–2.175)
< 0.001
< 0.001
1.533 (1.257–1.869)
< 0.001
 PSC
5
0.012
2.516 (0.808–7.832)
0.111
0.036
1.691 (0.633–4.517)
0.294
 Other
432
0.011
1.241 (1.014–1.518)
0.036
0.020
1.140 (0.984–1.321)
0.080
 Unknown
259
0.008
0.971 (0.755–1.247)
0.815
< 0.001
1.135 (0.961–1.339)
0.136
NSCLC non-small cell lung cancer, NLNs the number of removed lymph nodes, PSM propensity score matching, HR hazard ratio, CIs confident intervals, Lung NOS uncertain location on lung, Adeno adenocarcinoma, SCC squamous cell carcinoma, LCC large cell carcinoma, PSC pulmonary sarcomatoid carcinoma, Other other histological types
Table 3
The association between NLNs and CSS together with OS in univariate and multivariate analyses with PSM
  
CSS
OS
Variable
Number
Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
p value
HR (95%CIs)
p value
p value
HR (95%CIs)
p value
NLNs
 ≤ 5
2350
 
1 (reference)
  
1 (reference)
 
 > 5
2350
< 0.001
0.631 (0.557–0.714)
< 0.001
< 0.001
0.650 (0.597–0.708)
< 0.001
Sex
 Male
1908
 
1 (reference)
  
1 (reference)
 
 Female
2790
< 0.001
0.631 (0.557–0.714)
< 0.001
< 0.001
0.714 (0.657–0.777)
< 0.001
Age
 ≤ 65
1975
 
1 (reference)
  
1 (reference)
 
 > 65
2725
< 0.001
1.410 (1.244–1.599)
< 0.001
< 0.001
1.829 (1.671–2.002)
< 0.001
TNM stage
 IA1
699
 
1 (reference)
  
1 (reference)
 
 IA2
4001
0.005
1.153 (0.900–1.478)
0.261
0.003
1.117 (0.944–1.322)
0.197
Grade
 I
1055
 
1 (reference)
  
1 (reference)
 
 II
2044
< 0.001
2.094 (1.724–2.543)
< 0.001
< 0.001
1.642 (1.446–1.864)
< 0.001
 III
1187
< 0.001
2.762 (2.242–3.402)
< 0.001
< 0.001
2.055 (1.791–2.360)
< 0.001
 IV
64
0.007
1.574 (0.901–2.748)
0.111
0.007
1.248 (0.843–1.847)
0.268
 Unknown
350
0.005
1.643 (1.222–2.210)
0.001
0.037
1.277 (1.045–1.560)
0.017
Tumor location (%)
 Upper lobe
2783
      
 Middle lobe
294
0.640
  
0.158
  
 Lower lobe
1560
0.627
  
0.443
  
 Main bronchus
2
0.982
  
0.973
  
 Overlapping
20
0.891
  
0.977
  
 Lung NOS
41
0.079
  
0.230
  
Tumor size (mm)
< 0.001
1.019 (0.997–1.042)
0.094
< 0.001
1.014 (0.999–1.030)
0.066
Race
 American Indian
22
      
 Asian
289
0.820
  
0.225
  
 Black
393
0.455
  
0.865
  
 White
3989
0.667
  
0.924
  
 Unknown
7
0.978
  
0.967
  
Surgical methods
 Wedge resection
460
 
1 (reference)
  
1 (reference)
 
 Segmental resection
158
0.025
0.546 (0.392–0.761)
< 0.001
< 0.001
0.503 (0.396–0.638)
< 0.001
 Lobectomy
4060
< 0.001
0.339 (0.283–0.405)
< 0.001
< 0.001
0.353 (0.312–0.400)
< 0.001
 Pneumonectomy
22
0.533
0.581 (0.256–1.318)
0.194
0.225
0.537 (0.301–0.958)
0.035
 Unknown
0
NA
NA
NA
   
Histological types
 Adeno
3157
 
1 (reference)
  
1 (reference)
 
 SCC
1004
< 0.001
1.064 (0.915–1.237)
0.424
< 0.001
1.371 (1.240–1.516)
< 0.001
 LCC
116
< 0.001
1.640 (1.163–2.314
0.005
< 0.001
1.585 (1.228–2.045)
< 0.001
 PSC
1
0.981
0.000 (0.000–Inf)
0.981
0.981
0.000 (0.000–Inf)
0.972
 Other
270
0.140
1.140 (0.883–1.472)
0.314
0.082
1.117 (0.929–1.342)
0.240
 Unknown
152
0.575
0.867 (0.612–1.228)
0.422
0.008
1.086 (0.867–1.361)
0.472
NSCLC non-small cell lung cancer, NLNs the number of removed lymph nodes, PSM propensity score matching, HR hazard ratio, CIs confident intervals, Lung NOS uncertain location on lung, Adeno adenocarcinoma, SCC squamous cell carcinoma, LCC large cell carcinoma, PSC pulmonary sarcomatoid carcinoma, Other other histological types, Inf infinity
Besides, the patients who underwent lobectomy or wedge resection and with more than 5 LNs resected had a significantly better CSS (P < 0.001, P = 0.0095, respectively), while no significant impact on conferring better CSS was observed for segmental resection, and pneumonectomy, although the p values of segmental resection were near 0.05 (Fig. 3). Meanwhile, the number of dissected LNs contributed to the better OS of patients who underwent wedge resection, segmental resection, and lobectomy, (P < 0.001, P = 0.028, P = 0.0051, respectively) (Fig. 4).

Subgroup analysis of survival outcomes

Furthermore, a subgroup analysis was conducted to investigate the effect of listed factors in Table 1 on CSS and OS of eligible patients (without PSM). The effects of the rest of the variables on CSS and OS were illustrated in Figs. 5 and 6, respectively.

Discussion

This study examined the relationship between NLNs and the survival outcomes of patients with stage IA NSCLC ≤ 2 cm in size who underwent different types of lung surgeries. Kaplan–Meier analysis and log-rank test demonstrated that patients with more than 5 LNs dissected showed significantly better CSS and OS in the unmatched and matched patients, which indicates that dissection of more LNs might result in better survival. In addition, both univariable and multivariable analyses revealed that NLNs served as a protective prognostic predictor for CSS and OS in the unmatched and matched patients. Further, according to our subgroup study, patients who underwent wedge resection, segmental resection, or lobectomy rather than pneumonectomy, together with resection of more than 5 LNs, had statistically better survival outcomes. To sum up, patients with stage IA NSCLC ≤ 2 cm in size who undergo wedge resection, segmental resection, or lobectomy may have better survival outcomes after undergoing incremental NLNs.
To date, the relationship between NLNs and survival outcome for patients with stage IA NSCLC ≤ 2 cm in size remains controversial. Dissection of more LNs may result in a clearer TNM classification, a higher possibility to discover, and eradicate occult metastasis, and therefore a better survival outcome [9, 10]. Further, Burdett et al. noted that an increase in NLNs can make the pTNM stage more precise that it is beneficial to decide the strategy of adjuvant therapy [15]. Several retrospective studies based on the SEER database have confirmed the relationship between NLNs and survival outcomes of patients with stage N0 NSCLC and have proposed optimal NLNs for survival outcomes [4, 68]. Furthermore, Osarogiagbon et al. suggested that the resection of 11 to 15 LNs might be associated with better survival [6]. Similarly, Becker et al. observed a consistently increasing survival benefit for patients with 16 to 18 LNs removed [8]. Additionally, several single-center studies also highlighted the relationship. However, a study conducted by Saji et al. determined the optimal minimum NLNs as 8 for patients with stage I NSCLC [16]. Moreover, Wen et al. demonstrated that patients with stage T2N0M0 NSCLC should have at least 12 LNs resected during the surgery [5]. In addition, the minimal NLNs for patients with N0 NSCLC was not clear. Likewise, the NCCN guidelines indicate that N1 and N2 nodes should be dissected, and mapping should be performed; however, it does not specify the minimum NLNs [17]. Conversely, the European Society of Thoracic Surgeons guidelines proposes that at least six LNs from the hilar and mediastinal stations should be removed for accurate nodal staging [10].
Unfortunately, only a few studies have focused on whether NLNs is associated with the survival outcomes of patients with stage IA NSCLC 2 cm or less. Ding et al. demonstrated that 4 to 16 LNs should be examined for patients with NSCLC < 2 cm undergoing wedge resection, and these NLNs could provide a survival advantage to those patients. However, among patients who received segmentectomy, LN resection did not improve survival outcomes [7]. In Ding’s study, there were some stage IB patients, as they did not exclude the patients with pleura invasion. Wolf et al. showed that lobectomy led to superior survival compared to sub-lobar resection in patients with N0 NSCLC ≤ 2 cm; however, the survival outcome was not different from that in patients with LN resection performed together with lobectomy [18]. In contrast, our study revealed that LN resection conferred independent survival benefit to patients with NSCLC ≤ 2 cm, and NLNs contributed to survival benefit for patients who received wedge resection, segmental resection, or lobectomy, but not for patients who received pneumonotomy. Several theories can explain this phenomenon. There were only 45 patients who underwent pneumonectomy in comparison to a larger number of patients who received wedge resection, segmental resection, or lobectomy in our study (n = 1647, 364, 5228, respectively), and a small sample entails a risk of bias. Notably, the patients who received lobectomy or wedge resection and with more than 5 LNs dissected had a significantly better CSS, while there was no effect of dissection of more than 5 LNs with segmental resection, or pneumonectomy on CSS. The smaller sample sizes of patients undergoing segmental resection, or pneumonectomy might be responsible for it. Since p values of segmental resection were both near 0.05 (P = 0.055), and univariable and multivariable studies together with a subgroup study on OS revealed that all the four surgical methods except pneumonectomy together with dissection of more than 5 LNs contributed to better survival outcome, we concluded that patients who underwent wedge resection, segmental resection, or lobectomy had better survival outcome after having incremental NLNs.
There are several limitations to this study. Because of the retrospective nature of the study, the bias in our results was inevitably unremovable. However, the potential selection bias derived from a retrospective study was minimized by performing PSM. Due to the short follow-up period and a low malignancy rate of stage IA NSCLC tumors ≤ 2 cm, the median survival time of all patients was not identified. The exact location of the dissected LNs was unknown due to the statistical limitations. Moreover, our findings did not provide an exact optimal NLNs for LN dissection in clinical practice. Despite these limitations, we believe that our study could be used as a reference for the treatment of patients with stage IA NSCLC ≤ 2 cm in size who undergo wedge resection, segmental resection, or lobectomy.

Conclusions

In conclusion, NLNs was a strong prognosticator for patients who received wedge resection, segmental resection, or lobectomy rather than pneumonectomy. Our study indicates that patients with stage IA NSCLC ≤ 2 cm who undergo wedge resection, segmental resection, or lobectomy should undergo higher NLNs to achieve better OS, but the efficacy of our conclusions should be investigated further by a large-scale, prospective, multi-center study.

Acknowledgments

Our sincere thanks to colleagues in the Department of Thoracic Surgery, Sun Yat-sen University Cancer Center. Thanks to our respected pioneer, Professor Tie-Hua Rong, who oriented us to surgical oncology. We thank our patients who provided their information for medical research; they were the best teachers for doctors. We appreciate Editage (https://​app.​editage.​com/​) for reviewing and editing our manuscript.
The study protocol was approved by the Ethics Committee of Sun Yat-sen University Cancer Center (IRB No. B2019-116-01); the requirement of informed consent was waived
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.CrossRef
2.
Zurück zum Zitat Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:138–55.CrossRef Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:138–55.CrossRef
3.
Zurück zum Zitat Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615–22 discussion 622-613.CrossRef Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615–22 discussion 622-613.CrossRef
4.
Zurück zum Zitat Wu L-L, Liu X, Jiang W-M, et al. Stratification of patients with stage IB NSCLC based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual. Front Oncol. 2020;10:1–9. Wu L-L, Liu X, Jiang W-M, et al. Stratification of patients with stage IB NSCLC based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual. Front Oncol. 2020;10:1–9.
5.
Zurück zum Zitat Wen YS, Xi KX, Xi KX, et al. The number of resected lymph nodes is associated with the long-term survival outcome in patients with T2 N0 non-small cell lung cancer. Cancer Manag Res. 2018;10:6869–77.CrossRef Wen YS, Xi KX, Xi KX, et al. The number of resected lymph nodes is associated with the long-term survival outcome in patients with T2 N0 non-small cell lung cancer. Cancer Manag Res. 2018;10:6869–77.CrossRef
6.
Zurück zum Zitat Osarogiagbon RU, Ogbata O, Yu X. Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non–small cell lung cancer. Ann Thorac Surg. 2014;97:385–93.CrossRef Osarogiagbon RU, Ogbata O, Yu X. Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non–small cell lung cancer. Ann Thorac Surg. 2014;97:385–93.CrossRef
7.
Zurück zum Zitat Ding H, Wang H, Xu L, et al. Survival and resected lymph node number during sublobar resection for N0 non-small cell lung cancer 2 cm or less. Ann Thorac Surg. 2019;107:1647–55.CrossRef Ding H, Wang H, Xu L, et al. Survival and resected lymph node number during sublobar resection for N0 non-small cell lung cancer 2 cm or less. Ann Thorac Surg. 2019;107:1647–55.CrossRef
8.
Zurück zum Zitat Becker DJ, Levy BP, Gold HT, et al. Influence of extent of lymph node evaluation on survival for pathologically lymph node negative non–small cell lung cancer. Am J Clin Oncol. 2018;41:820–5.CrossRef Becker DJ, Levy BP, Gold HT, et al. Influence of extent of lymph node evaluation on survival for pathologically lymph node negative non–small cell lung cancer. Am J Clin Oncol. 2018;41:820–5.CrossRef
9.
Zurück zum Zitat Nomori H, Mori T, Izumi Y, et al. Is completion lobectomy merited for unanticipated nodal metastases after radical segmentectomy for cT1 N0 M0/pN1-2 non–small cell lung cancer? J Thorac Cardiovasc Surg. 2012;143:820–4.CrossRef Nomori H, Mori T, Izumi Y, et al. Is completion lobectomy merited for unanticipated nodal metastases after radical segmentectomy for cT1 N0 M0/pN1-2 non–small cell lung cancer? J Thorac Cardiovasc Surg. 2012;143:820–4.CrossRef
10.
Zurück zum Zitat De Leyn P, Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32:1–8.CrossRef De Leyn P, Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32:1–8.CrossRef
11.
Zurück zum Zitat Yang W, Sun Y, Fang W, et al. High-resolution computed tomography features distinguishing benign and malignant lesions manifesting as persistent solitary subsolid nodules. Clin Lung Cancer. 2018;19:e75–83.CrossRef Yang W, Sun Y, Fang W, et al. High-resolution computed tomography features distinguishing benign and malignant lesions manifesting as persistent solitary subsolid nodules. Clin Lung Cancer. 2018;19:e75–83.CrossRef
12.
Zurück zum Zitat Liu Y, Wang H, Li Q, et al. Radiologic features of small pulmonary nodules and lung cancer risk in the national lung screening trial: a nested case-control study. Radiology. 2018;286:298–306.CrossRef Liu Y, Wang H, Li Q, et al. Radiologic features of small pulmonary nodules and lung cancer risk in the national lung screening trial: a nested case-control study. Radiology. 2018;286:298–306.CrossRef
13.
Zurück zum Zitat Suzuki K, Koike T, Asakawa T, et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011;6:751–6.CrossRef Suzuki K, Koike T, Asakawa T, et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011;6:751–6.CrossRef
14.
Zurück zum Zitat Suzuki K, Watanabe S, Wakabayashi M et al. A single-arm study of sublobar resection for ground glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg. 2020: In press. Suzuki K, Watanabe S, Wakabayashi M et al. A single-arm study of sublobar resection for ground glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg. 2020: In press.
16.
Zurück zum Zitat Saji H, Tsuboi M, Yoshida K, et al. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol. 2011;6:1865–71.CrossRef Saji H, Tsuboi M, Yoshida K, et al. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol. 2011;6:1865–71.CrossRef
18.
Zurück zum Zitat Wolf AS, Richards WG, Jaklitsch MT, et al. Lobectomy versus sublobar resection for small (2 cm or less) non-small cell lung cancers. Ann Thorac Surg. 2011;92:1819–23 discussion 1824-1815.CrossRef Wolf AS, Richards WG, Jaklitsch MT, et al. Lobectomy versus sublobar resection for small (2 cm or less) non-small cell lung cancers. Ann Thorac Surg. 2011;92:1819–23 discussion 1824-1815.CrossRef
Metadaten
Titel
Association between number of dissected lymph nodes and survival in stage IA non-small cell lung cancer: a propensity score matching analysis
verfasst von
Lei-Lei Wu
Jia-Jian Lai
Xuan Liu
Yang-Yu Huang
Peng Lin
Hao Long
Lan-Jun Zhang
Guo-Wei Ma
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2020
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-020-02090-5

Weitere Artikel der Ausgabe 1/2020

World Journal of Surgical Oncology 1/2020 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.